Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 9/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 9/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 8/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4913611 | 0.90 | OPRM1 (0.52) | HRH3OPRM1OPRD1OPRK1ESR2 | |
| SCHEMBL3077276 | 0.89 | HRH3 (0.66) | HRH3OPRM1OPRD1OPRK1ESR2 | |
| SCHEMBL3077662 | 0.86 | HRH3 (0.52) | HRH3ESR2NR1H2 | |
| SCHEMBL4925258 | 0.85 | ESR2 (0.47) | HRH3OPRM1OPRD1OPRK1ESR2 | |
| SCHEMBL5430656 | 0.85 | ESR2 (0.47) | HRH3OPRM1OPRD1OPRK1ESR2 | |
| SCHEMBL5664186 | 0.85 | GPR119 (0.49) | ESR2NR1H2 | |
| SCHEMBL3691958 | 0.83 | OPRM1 (0.60) | HRH3OPRM1OPRD1OPRK1NR1H2 | |
| SCHEMBL3693963 | 0.83 | OPRM1 (0.62) | HRH3OPRM1OPRD1OPRK1ESR2 | |
| SCHEMBL5451256 | 0.82 | HRH3 (0.57) | HRH3OPRM1OPRD1OPRK1ESR2 | |
| SCHEMBL5462270 | 0.82 | GPR119 (0.49) | ESR2NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080009479-A1 | Tetrahydrobenzazepines as Histamine H3 Receptor Ligands | GLAXO GROUP LIMITED (GB) | 2008-01-10 | — | — | US | disclosed |
| US-20070232590-A1 | 3-Cylcoalkylbenzazepines as Histamine H3 Antagonists | GLAXO GROUP LIMITED (GB) | 2007-10-04 | — | — | US | disclosed |
| US-20070232590-A1 | 3-Cylcoalkylbenzazepines as Histamine H3 Antagonists | GLAXO GROUP LIMITED (GB) | 2007-10-04 | — | — | US | disclosed |
| US-20070232590-A1 | 3-Cylcoalkylbenzazepines as Histamine H3 Antagonists | GLAXO GROUP LIMITED (GB) | 2007-10-04 | — | — | US | disclosed |
| EP-1756094-A1 | 3-CYCLOALKYLBENZAZEPINES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2007-02-28 | — | — | EP | disclosed |
| EP-1735299-A1 | TERTRAHYDROBENZAZEPINES AS HISTAMINE H3 RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005123723-A1 | 3-CYCLOALKYLBENZAZEPINES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2005-12-29 | — | — | WO | disclosed |
| WO-2005097778-A1 | TETRAHYDROBENZAZEPINES AS HISTAMINE H3 RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009479-A1 | Tetrahydrobenzazepines as Histamine H3 Receptor Ligands | HRH3, HRH4, HRH1 | HRH3 1/4885OPRM1 155/4885OPRD1 163/4885 |
| US-20070232590-A1 | 3-Cylcoalkylbenzazepines as Histamine H3 Antagonists | HRH3, HRH4, HRH2 | HRH3 1/4885OPRM1 548/4885OPRD1 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.